Compass Pathways Unveils Investor Presentation Highlighting Progress in Psilocybin Therapy for Depression and PTSD

Reuters11-04

Compass Pathways Unveils Investor Presentation Highlighting Progress in Psilocybin Therapy for Depression and PTSD

Compass Pathways plc has shared updates on its ongoing clinical programs targeting treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). The company highlighted a large unmet need in the TRD market, with approximately 3 million patients in the U.S. alone. Data from the Phase 3 COMP005 trial showed that COMP360 psilocybin achieved the primary endpoint, with a clinically meaningful mean treatment difference of -3.6 points on the MADRS depression scale compared to placebo (p<0.001). Safety data reviewed by the Data Safety Monitoring Board indicated no new or unexpected findings and no evidence of a clinically meaningful imbalance in suicidality between treatment arms. Additional efficacy data demonstrated a rapid and durable response following a single dose of COMP360. Upcoming data releases from ongoing trials are expected in 2026. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief on November 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2580758923?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 22:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580758923","market":"us","top_or_hot":-1,"title":"Compass Pathways Unveils Investor Presentation Highlighting Progress in Psilocybin Therapy for Depression and PTSD","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Compass Pathways Unveils Investor Presentation Highlighting Progress in Psilocybin Therapy for Depression and PTSD\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Compass Pathways plc has shared updates on its ongoing clinical programs targeting treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). The company highlighted a large unmet need in the TRD market, with approximately 3 million patients in the U.S. alone. Data from the Phase 3 COMP005 trial showed that COMP360 psilocybin achieved the primary endpoint, with a clinically meaningful mean treatment difference of -3.6 points on the MADRS depression scale compared to placebo (p&lt;0.001). Safety data reviewed by the Data Safety Monitoring Board indicated no new or unexpected findings and no evidence of a clinically meaningful imbalance in suicidality between treatment arms. Additional efficacy data demonstrated a rapid and durable response following a single dose of COMP360. Upcoming data releases from ongoing trials are expected in 2026. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Compass Pathways Unveils Investor Presentation Highlighting Progress in Psilocybin Therapy for Depression and PTSD</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCompass Pathways Unveils Investor Presentation Highlighting Progress in Psilocybin Therapy for Depression and PTSD\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 22:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Compass Pathways Unveils Investor Presentation Highlighting Progress in Psilocybin Therapy for Depression and PTSD\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Compass Pathways plc has shared updates on its ongoing clinical programs targeting treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). The company highlighted a large unmet need in the TRD market, with approximately 3 million patients in the U.S. alone. Data from the Phase 3 COMP005 trial showed that COMP360 psilocybin achieved the primary endpoint, with a clinically meaningful mean treatment difference of -3.6 points on the MADRS depression scale compared to placebo (p&lt;0.001). Safety data reviewed by the Data Safety Monitoring Board indicated no new or unexpected findings and no evidence of a clinically meaningful imbalance in suicidality between treatment arms. Additional efficacy data demonstrated a rapid and durable response following a single dose of COMP360. Upcoming data releases from ongoing trials are expected in 2026. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL1QSMfl:1","article_id":"2580758923","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580758923","pubTimestamp":1762266663,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Compass Pathways plc has shared updates on its ongoing clinical programs targeting treatment-resistant depression  and post-traumatic stress disorder . The company highlighted a large unmet need in the TRD market, with approximately 3 million patients in the U.S. alone. Data from the Phase 3 COMP005 trial showed that COMP360 psilocybin achieved the primary endpoint, with a clinically meaningful mean treatment difference of -3.6 points on the MADRS depression scale compared to placebo . Safety data reviewed by the Data Safety Monitoring Board indicated no new or unexpected findings and no evidence of a clinically meaningful imbalance in suicidality between treatment arms. Additional efficacy data demonstrated a rapid and durable response following a single dose of COMP360. Upcoming data releases from ongoing trials are expected in 2026. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CMPS":"COMPASS Pathways plc"},"translate_title":"Compass Pathways推出投资者演示文稿，重点介绍裸盖菇素治疗抑郁症和PTSD的进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMPS":0.9},"content_text":"Compass Pathways Unveils Investor Presentation Highlighting Progress in Psilocybin Therapy for Depression and PTSD\n    \n\n        Compass Pathways plc has shared updates on its ongoing clinical programs targeting treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). The company highlighted a large unmet need in the TRD market, with approximately 3 million patients in the U.S. alone. Data from the Phase 3 COMP005 trial showed that COMP360 psilocybin achieved the primary endpoint, with a clinically meaningful mean treatment difference of -3.6 points on the MADRS depression scale compared to placebo (p<0.001). Safety data reviewed by the Data Safety Monitoring Board indicated no new or unexpected findings and no evidence of a clinically meaningful imbalance in suicidality between treatment arms. Additional efficacy data demonstrated a rapid and durable response following a single dose of COMP360. Upcoming data releases from ongoing trials are expected in 2026. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief on November 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2580758923","isCrawlerRequest":true}